Vanta Bioscience Ltd

Vanta Bioscience Ltd has announced that its Board of Directors will convene on November 13, 2026, to approve the standalone and consolidated unaudited financial results for the half-year ended September 30, 2026. The meeting will also include a review of the Limited Review Report from the statutory auditors. In line with the Insider Trading Policy, the trading window for designated persons remains closed from October 1, 2026, to November 15, 2026.

Vanta Bioscience Ltd has announced that its Board of Directors will convene on November 13, 2026, to consider and approve the standalone and consolidated unaudited financial results for the half-year ended September 30, 2026. The meeting will also include a review of the Limited Review Report from the statutory auditors. In line with insider trading policies, the trading window for designated persons remains closed from October 1, 2026, to November 15, 2026.

Vanta Bioscience Ltd has announced the closure of its trading window for all designated persons, their immediate relatives, and concerned individuals. This closure is in accordance with the company's Code of Conduct for Prohibition of Insider Trading and SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will remain shut from Thursday, October 01, 2026, until 48 hours after the declaration of the company's Unaudited Financial Results for the half-year ended September 30, 2026. The date for the board meeting to consider these results will be announced later.

Vanta Bioscience Ltd has filed its Annual Report for the Financial Year 2025-26 and the Notice of its 10th Annual General Meeting (AGM). The report, available on the company's website, includes sections on corporate information, board's report, management discussion and analysis, and detailed standalone and consolidated financial statements. The AGM is scheduled for September 30, 2026. The filing also lists the company's directors, key management personnel, auditors, and bankers.

Vanta Bioscience Ltd announced that its Board of Directors, in a meeting held on September 5, 2026, approved the Annual Report for the financial year 2025-26. The Board also fixed the date, time, and venue for the 10th Annual General Meeting (AGM), which will be held on September 30, 2026, at 10:00 AM IST in Secunderabad, Telangana. Details regarding e-voting, including cut-off dates and timings, were also provided.

Vanta Bioscience Ltd's Board of Directors approved the audited standalone and consolidated financial results for the half year and financial year ended March 31, 2026. Mr. Dopesh Raja Mulakala has been re-appointed as Managing Director for another 3 years effective April 18, 2026, subject to shareholder approval. The statutory auditors, M/s Mathesh & Ramana, issued an unmodified opinion on the financial results. For FY26, Vanta Bioscience reported total revenue of ₹167.41 Lacs and a net profit of ₹1.81 Lacs.

Vanta Bioscience Ltd's board approved audited standalone and consolidated financial results for the half year and financial year ended March 31, 2026. Mr. Dopesh Raja Mulakala has been re-appointed as Managing Director for another 3 years effective April 18, 2026, subject to shareholder approval. The statutory auditors, M/s Mathesh & Ramana, issued an unmodified opinion on the financial results. The meeting was held on May 30, 2026, from 6:00 PM to 7:00 PM.

Vanta Bioscience Ltd has scheduled a Board of Directors meeting on May 30, 2026, to consider and approve the Standalone and Consolidated Audited Financial Results for the half year and financial year ended March 31, 2026. The board will also review the Audit Reports issued by the Statutory Auditors. The Trading Window remains closed from April 01, 2026, until June 1, 2026, for designated persons as per the Insider Trading Policy.

Vanta Bioscience Ltd has announced the closure of its trading window for all designated persons, their immediate relatives, and all other concerned persons. This closure is in accordance with the Company’s Code of Conduct for Prohibition of Insider Trading and the SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will remain closed from Wednesday, April 01, 2026 till the expiry of 48 hours after the declaration of the Audited Financial Results of the Company for the half year and year ended March 31, 2026. The date of the board meeting for consideration and declaration of the Audited Financial Results will be intimated in due course.

Vanta Bioscience Ltd has clarified that it has disclosed all material information to BSE Ltd, as required by the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company is not aware of any reason for significant movement in the price of its shares, stating that the movement is market-driven and not connected to the company's management. The company reiterates its commitment to adhere to all compliances under the Listing Regulations and other applicable laws.